Loading
A phase 1/2 trial of MCLA-129 in non-small-cell lung cancer and small-cell lung cancer, run by Betta Pharmaceuticals Co., Ltd., now recruiting.
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors is a phase 1/2 interventional study registered as NCT04930432 by Betta Pharmaceuticals Co., Ltd., with 400 participants planned, started 2021-09-24 and due to reach its primary completion in 2028-04-30. Interventions recorded: MCLA-129. Conditions listed: Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares MCLA-129, Small-cell lung cancer, Colorectal cancer, Non-small-cell lung cancer.
Shares MCLA-129, Betta Pharmaceuticals.
Shares MCLA-129, Betta Pharmaceuticals.
Shares Betta Pharmaceuticals, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/